Do Urate Targets Influence CV Risk?

Researchers examine whether achieving treat-to-target serum urate levels with urate-lowering treatment affects long-term cardiovascular outcomes in patients with gout.

By
Kathryn Wighton
January 30, 2026
3 min

Conexiant

Overview

Revise to include the study's population size and clarify the significance of the findings.

Background

Gout is associated with increased cardiovascular risk, making effective management crucial. The treat-to-target approach for urate-lowering therapy aims to achieve specific serum urate levels to mitigate these risks. Understanding the relationship between urate levels and cardiovascular outcomes can enhance treatment strategies for patients with gout.

Data Highlights

Measure	Result
Percentage achieving urate target (<6 mg/dL)	27%
Relative risk reduction for MACE (<6 mg/dL)	9%
Relative risk reduction for MACE (<5 mg/dL)	23%
5-year cardiovascular event-free survival (treat-to-target)	89%
5-year cardiovascular event-free survival (non-treat-to-target)	88%

Key Findings

Only 27% of gout patients achieved the serum urate target of <6 mg/dL within 12 months.
Achieving serum urate levels <6 mg/dL was associated with a 9% relative risk reduction for major adverse cardiovascular events (MACE).
A more stringent target of <5 mg/dL was linked to a 23% relative risk reduction for MACE.
5-year cardiovascular event-free survival was 89% in the treat-to-target group compared to 88% in the non-treat-to-target group.
Treat-to-target therapy was associated with fewer gout flares.
Observational study limitations include potential residual confounding and exposure misclassification.

Clinical Implications

Clinicians should prioritize achieving serum urate targets in gout management to reduce cardiovascular risks. The findings support the use of a treat-to-target approach, particularly for patients with high cardiovascular risk. Regular monitoring and adjustment of urate-lowering therapy may enhance patient outcomes.

Conclusion

The study underscores the importance of achieving serum urate targets in gout management to mitigate cardiovascular risks. Further research is needed to confirm these findings and optimize treatment strategies.